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decrease the likelihoodofdiscoveringunknowntoxiceffects in
largerpopulationsandcostlyphase2and3studies.That (2)pro-
spectivelydelineatingtherapeutic intentwithprespecifiedclini-
cal endpoints shouldbeadoptedbecause itmay facilitateearly
identificationofefficacyandimprove insurancecoverageofand
patient access to early-phase trials.2 The ability to directly at-
tribute late toxic effects to specific drug radiation combina-
tions is complicated by early patient mortality and confound-
ing treatments.However,because investigatorsareobligated to
their patients and peers to evaluate toxic effects from investi-
gational treatments, we propose that (3) assessment and re-
porting of late toxic effects be included in phase 1 trials.
Limitations of this study include the time period evalu-
ated, that it is a single database query, and that it only includes
published trials and toxic effects.ClinicalTrials.govwasnot in-
cluded because trial registration is not mandated as a condi-
tionofpublication forphase 1 trials.6However, thesedata iden-
tify3 importantmeasures,which if addressed,will improve the
quality, availability, and interpretability of phase 1 trials.
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Chemotherapy-Related Chronic
Myelogenous Leukemia: A Case Series
of PatientsWith GermCell Tumor
Germcell tumors (GCTs) are themost commoncancer inyoung
men ages 15 to 35 years and are uniquely responsive to che-
motherapy,with cure rates approaching80%.Late adverse ef-
fects of treatment can manifest throughout the lifetime of a
cured patientwhowill be at increased risk of solid and hema-
tologicmalignant neoplasms.1,2 Etoposidehas becomeoneof
the cornerstones of platinum-containing regimens for GCT.
Treatment with etoposide entails a known risk of secondary
leukemia that typically exhibits a short latencyperiod, a chro-
mosomal translocation (11q23 and 21q22), and rearrange-
ment of the mixed-lineage leukemia gene.
Methods | We observed 3 patients with Philadelphia chromo-
some-positive chronic myelogenous leukemia (CML) follow-
ing therapy for GCT.
Results | Case 1. In 1999, a man in his mid-30s with nonsemi-
nomatous GCT (NSGCT) was treated with orchiectomy fol-
lowed by 4 courses of bleomycin, etoposide, and cisplatin. In
September 2011, hewasnoted tohave awhite blood cell count
(WBC) of 111 700/μL (111.7 × 109/L). Bone marrow examina-
tion showedmorphologic findings of chronic-phaseCML, and
a t(9;22)(q34;q11) was identified. The patient started treat-
mentwith imatinib andachieveda completemolecular remis-
sion. Unfortunately, in 2014, he developed malignant trans-
formationof teratoma to anundifferentiatedneuroendocrine
carcinoma with unresectable hepatic metastases and died of
his disease.
Case 2. In 2006, a man in his early 30s had orchiectomy for
clinical stage I NSGCT and elected to receive a single cycle of
BEP. In November 2006, the disease relapsed, and he was
treated with 3 cycles of etoposide, ifosfamide, and cisplatin
(VIP). In 2007, the patient experienced a second relapse and
was treatedwith 2 cycles of high-dose carboplatin and etopo-
side followedbyperipheral blood stemcell rescue. In 2011, he
was found to have leukocytosis (WBC, 91 700/μL [91.7 × 109/
L]). Bonemarrowexamination confirmed chronic-phaseCML
with t(9;22)(q34;q11). The patient was treated with dasatinib
and achieved amolecular remission . Todate, he continues to
be in remission for his CML and recurrent GCT.
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Case 3. In 2012, a young adult manwith history of Klinefelter
syndrome presented with intermittent chest pain and was
found to have a 15-cm primary mediastinal NSGCT. He was
treated with 4 cycles of VIP followed by resection of residual
mediastinal mass, which revealed teratoma. In 2014, he was
found to have leukocytosis (WBC, 44000/μL [44.0 × 109/
L]). Bone marrow examination confirmed chronic-phase
CML by morphologic characteristics, and a t(9;22)(q34;q11)
was identified by chromosome analysis. The patient started
treatment with dasatinib and achieved a hematologic
response. To date, his BCR/ABL transcript declined appropri-
ately from 55% to 9%. He continues to be in remission for his
GCT.
Discussion | There have been reports of chemotherapy-related
Philadelphia-chromosome leukemias in patients with ante-
cedent malignant neoplasms.3 Past treatments for GCT with
cisplatin-etoposide–containing regimens or HDCT with car-
boplatin-etoposidehavebeen linkedtoan increasedriskof sec-
ondary acute leukemia1,4 and solid tumors.5 A review of the
literature reveals 7 cases of GCT with subsequent develop-
ment of CML.1,3,6 In this series, we present 3 cases of patients
withGCTwhoachievedremissionwithchemotherapyandlater
developed BCR/ABL-positive CML. These findings raise the
question of a causal relationship between etoposide and/or
platinum-containing chemotherapy and the development of
CML with t(9;22)(q34;q11).
Etoposide-basedchemotherapy inpatientswithGCTis leu-
kemogenic. It is not clear whether combination chemo-
therapy with cisplatin and bleomycin contribute to this re-
sult. While its association with AML is well established,
questions regarding theconnectionof etoposideandcisplatin-
containingcombinationchemotherapyandsecondaryCMLare
posed herein. The relatively low risk of secondary leukemia
inpatients treatedwithpotentially curative combination che-
motherapy forGCTcontinues tobe reassuring.1However, phy-
sicians should be aware of possible late toxic effects of these
treatment regimensandtheneedfordiligent follow-up in these
patients.
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Disease-Specific Hashtags for Online
Communication About Cancer Care
Increasingly, patients, caregivers, andhealth care profession-
als (HCPs) go online to learn about and discuss cancer care.1
However, finding other people or organizations with similar
interests can be difficult without some structure.
Hashtagsareuser-generated tags that canorganizeandag-
gregate content on social networks. In July 2011, 2 patient ad-
vocates started a breast cancer chat on Twitter using the tag
#bcsm (breast cancer social media); one of us (D.J.A.) joined
as a comoderator. This same model but with hashtag #btsm
was used to discuss brain tumors in January 2012. Both tags
are now regularly usedonTwitter bypatients, caregivers, and
HCPs.
Dedicated hashtags may make it easier to engage in rel-
evant conversations online for other types of cancer. In this
study,wedescribe away tousedisease-specifichashtags simi-
lar to #bcsm and #btsm to organize and increase online dis-
cussion of cancer care.
Methods | Based on the models using the #bcsm and #btsm
hashtags, 2 of us (M.S.K. and P.F.A.) developed a set of 23 new
cancer-specific tags that met the following criteria: disease
specific, short, unique orminimally used on Twitter, and end-
ing in “sm” for “social media” (as a prompt that online use is
public). We selected this design to balance practical use with
the ability to organize content. Initially proposed in July 2013,
this cancer tag ontology (CTO) was posted on Symplur in
November 2013 after public commentary and engagement
(Table).2
We analyzed the number of tweets and users of the tags
quarterly from April 2011 through June 2015 using Symplur
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